SAINT-PREX, Switzerland - Wednesday, November 30th 2016 [ME NewsWire]
(BUSINESS WIRE)-- Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced a long-term collaboration aimed at improving the bioavailability, efficacy and safety profile of oral therapeutic medicines through nanotechnology. Potential benefits of research in this area include a reduction of adverse effects, increased patient adherence to treatment and more convenient dosing.
From 2017, a joint R&D centre and programme, named Nanotechnology Innovation Laboratory Enterprise (NILE), will be housed at Aché’s R&D centre in São Paulo, Brazil, funded by Ferring and Aché and governed by a joint steering committee.
The centre will explore nanotechnology as a delivery system for future medicines through programmes designed to match each company’s therapeutic needs. For Ferring, this means a focus on peptides and proteins in reproductive health, gastroenterology an
Read more »